Is Business Broken?
Life Science Innovation: Who Should Pay?
Sep 26, 2024
In this engaging discussion, U.S. Representative Jake Auchincloss advocates for sustainable healthcare policies, while Michael Sherman shares insights on funding innovative therapies amidst high costs. Andrew Obenshain emphasizes Bluebird Bio's mission to pioneer gene therapies for genetic diseases. They tackle the complex interplay between innovation and accessibility, proposing collaborative funding models to improve patient access and addressing ethical considerations surrounding expensive treatments. Together, they envision a future where groundbreaking therapies are within reach for all.
42:15
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The high costs of gene and cell therapies necessitate innovative financing and insurance reforms to ensure patient access without financial strain.
- Policymakers should shift the focus from immediate costs to the long-term societal benefits and savings provided by effective treatments for chronic conditions.
Deep dives
Revolutionary Potential of Gene and Cell Therapies
Gene and cell therapies represent groundbreaking advancements in medicine, offering potential cures for chronic genetic diseases that previously lacked effective treatments. These therapies work by correcting genetic defects, with the first successful treatments emerging after decades of research and failed attempts since the 1980s. Companies like Bluebird Bio have developed therapies for severe conditions such as adrenoleukodystrophy and hemoglobinopathies, allowing patients to live healthier lives free from debilitating symptoms. The complexity of these treatments is underscored by their bespoke manufacturing processes, which result in significant costs, often exceeding millions of dollars per patient.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
